Compare LMNR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | PALI |
|---|---|---|
| Founded | 1893 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 240.2M |
| IPO Year | 2005 | 2019 |
| Metric | LMNR | PALI |
|---|---|---|
| Price | $13.30 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.00 | $11.29 |
| AVG Volume (30 Days) | 87.2K | ★ 3.9M |
| Earning Date | 03-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $12.20 | $0.55 |
| 52 Week High | $17.11 | $2.64 |
| Indicator | LMNR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 58.09 |
| Support Level | $12.73 | $1.57 |
| Resistance Level | $14.86 | $2.36 |
| Average True Range (ATR) | 0.41 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 57.46 | 86.03 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.